The teachings provided herein generally relate to enhanced antivirulents that inactivate antibiotic-resistant bacteria as opposed to relying on an antimicrobial killing of the bacteria, and the antivirulents are safe for oral administration. As such, the systems taught herein are valuable methods that provide an alternate pathway for treating a subject having an antibiotic-resistant bacterial infection.

Embodiments of the disclosure encompass methods and compositions related to treatment of Acute Respiratory Distress Syndrome caused by any reason, including caused by a coronavirus, for example. In particular embodiments, fibroblasts are delivered to an individual in need thereof to stimulate generation of T regulatory cells that may or may not be FoxP3-positive, and/or immune regulatory cells previously exposed to fibroblasts are delivered to the individual.

Embodiments of the disclosure encompass methods and compositions related to treatment of Acute Respiratory Distress Syndrome caused by any reason, including caused by a coronavirus, for example. In particular embodiments, fibroblasts are delivered to an individual in need thereof to stimulate generation of T regulatory cells that may or may not be FoxP3-positive, and/or immune regulatory cells previously exposed to fibroblasts are delivered to the individual.

Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities.

Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities.

A method of preventing or treating solid and soft tumors and proliferative diseases in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of treating solid and soft tumors and proliferative diseases and wherein the plant species is selected from the group consisting of Nigella sativa, Thymuscapitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum, Rhus coriaria, Gynostemma pentaphyllum, Boswellia sacra and Panaxginseng, preventing or treating solid and soft tumors and proliferative diseases in the subject.

A method of preventing or treating solid and soft tumors and proliferative diseases in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of treating solid and soft tumors and proliferative diseases and wherein the plant species is selected from the group consisting of Nigella sativa, Thymuscapitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum, Rhus coriaria, Gynostemma pentaphyllum, Boswellia sacra and Panaxginseng, preventing or treating solid and soft tumors and proliferative diseases in the subject.

A method of preventing or treating solid and soft tumors and proliferative diseases in a subject in need thereof is provided. The method comprising administering to the subject an effective amount of a plant species or genus thereof-derived component selected from the group consisting of a plant part, extract thereof, fraction thereof, active ingredient thereof, synthetic analog thereof, mimetic thereof or combination thereof, wherein the component is capable of treating solid and soft tumors and proliferative diseases and wherein the plant species is selected from the group consisting of Nigella sativa, Thymuscapitatus, Thymus vulgaris, Origanum syriacum, Thymbra spicata, Satujera thymbra, Sesamum indicum, Rhus coriaria, Gynostemma pentaphyllum, Boswellia sacra and Panaxginseng, preventing or treating solid and soft tumors and proliferative diseases in the subject.

The present invention relates to a novel use of an Anemarrhena asphodeloides Bunge extract and the like, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a fraction thereof or a compound isolated therefrom as an active ingredient. In addition, the present invention relates to a novel use of a combined extract of medicinal herbs, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a Galla Rhois extract, a Codonopsis lancellata extract, and the like as active ingredients, or including an Anemarrhena asphodeloides Bunge extract, a Coptis japonica Makino extract, and the like as active ingredients. According to the present invention, the Anemarrhena asphodeloides Bunge extract and the like or the combined extract can be used as a food or medical materials constituting a pharmaceutical composition or a nutraceutical composition. The pharmaceutical composition or the nutraceutical composition can be used for preventing or treating acute colitis or chronic colitis, and particularly, can effectively prevent, delay, alleviate or treat inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and the like.

The present invention relates to a novel use of an Anemarrhena asphodeloides Bunge extract and the like, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a fraction thereof or a compound isolated therefrom as an active ingredient. In addition, the present invention relates to a novel use of a combined extract of medicinal herbs, and provides a composition for preventing or treating colitis, including an Anemarrhena asphodeloides Bunge extract, a Galla Rhois extract, a Codonopsis lancellata extract, and the like as active ingredients, or including an Anemarrhena asphodeloides Bunge extract, a Coptis japonica Makino extract, and the like as active ingredients. According to the present invention, the Anemarrhena asphodeloides Bunge extract and the like or the combined extract can be used as a food or medical materials constituting a pharmaceutical composition or a nutraceutical composition. The pharmaceutical composition or the nutraceutical composition can be used for preventing or treating acute colitis or chronic colitis, and particularly, can effectively prevent, delay, alleviate or treat inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and the like.